BioMedNewsBreaks

TuesdayAug 13, 2019 9:59 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Recent Achievements as Part of Overall Expansion Strategy

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its recent achievements as part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex(TM) immunogene therapy, to commercialization. Per the update, Genprex has published recent as well as historical achievements to its newly launched, interactive corporate timeline, which can be found on the company’s website. “Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth…

Continue Reading

TuesdayAug 06, 2019 11:02 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Manufacturing Partner Aldevron Completes Significant Manufacturing Step for Initial Product Candidate, Oncoprex(TM)

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA per the manufacturing agreement between the companies that was disclosed in September 2018. According to the update, Genprex’s Oncoprex(TM), the company’s initial product candidate, consists of a TUSC2 plasmid DNA manufactured by Aldevron encapsulated in a nanovesicle made from lipid molecules with a positive electrical charge. Historically, manufacturing steps have been done for Genprex at MD Anderson Cancer Center, but, since Genprex’s IPO, the company has been working to transfer and…

Continue Reading

WednesdayJul 31, 2019 10:37 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Initiates First Phase of Branding Lead Drug Candidate

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced it has initiated the first phase of branding its lead drug candidate, Oncoprex(TM) immunogene therapy, and has completed and submitted non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (“USAN”) Council. According to the update, Genprex will, upon receipt of USAN feedback expected later this year, submit its non-proprietary drug name selections to the World Health Organization for International Nonproprietary Names (“INN”) status. By mid-2020, the company expects to obtain an approved non-proprietary drug name. “Developing and obtaining regulatory approval of a non-proprietary drug name is…

Continue Reading

MondayJul 01, 2019 10:33 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Update on Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning provided an update on the development of its lead drug candidate, Oncoprex(TM) immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (“NSCLC”). Based on data from the ongoing study through GNPX’s July 2018 sponsored research agreement with The University of Texas MD Anderson Cancer Center, as well as prior clinical and pre-clinical studies, Genprex is working with its scientific advisory board and outside consultants to design a clinical trial for Oncoprex. According to the update, the new study will focus on Oncoprex in combination with…

Continue Reading

TuesdayJun 11, 2019 12:33 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Advances Toward Lead Drug Candidate Commercialization through Retaining Addison Whitney to Oversee Naming Process

Genprex (NASDAQ: GNPX), a clinical-stage, gene-therapy company, recently announced that it has retained pharmaceutical branding agency Addison Whitney to assist with the naming of the company’s leading drug candidate (http://nnw.fm/4arQW). An article further discussing the company reads, “Addison Whitney has a proven track record of branding success within the pharmaceutical market. It enables clients to achieve growth through both brand differentiation and creative naming practices. Its most recent successes include guiding pharmaceutical companies such as Merck, Celgene and Roche through the regulatory steps needed for name approval. . . . According to Genprex Chairman and CEO Rodney Varner, retaining the services…

Continue Reading

WednesdayJun 05, 2019 2:41 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Developing Gene Therapy-based Approach to Treat Non-small Cell Lung Cancer

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is developing Oncoprex immunogene therapy as an innovative, gene therapy-based approach for the treatment of non-small cell lung cancer (“NSCLC”). An article further discussing the company reads, “NSCLC is the most common type of lung cancer. It accounts for approximately 85% of all lung-cancer cases, and despite the development of innovative treatment strategies, the survival rate for lung cancer patients has not improved significantly over the past 25 years (http://nnw.fm/0YVIu) . . . . Breakthrough technologies and therapeutic approaches like those developed by Genprex could take cancer treatment solutions to a new level of…

Continue Reading

TuesdayMay 21, 2019 11:45 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Details Plans to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene-therapy company, this morning announced that it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019. Per the update, Genprex President and COO Julien Pham, MD, MPH, will lead the company’s presentation at 11:10 a.m. CT in the Waldorf Astoria Chicago’s Sinclair Ballroom. Pham will also be available for one-on-one meetings at the event. To view the full press release, visit http://nnw.fm/MgN2d About Genprex Inc. Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer…

Continue Reading

FridayMay 17, 2019 1:14 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Taking Unique Gene Therapy Approach to Cancer Treatment

Genprex (NASDAQ: GNPX) is a clinical-stage, gene-therapy company focused on the advancement of its lead drug candidate, Oncoprex(TM) immunogene therapy. Oncoprex is an investigational therapy for non-small cell lung cancer (“NSCLC”). An article discussing the company reads, “Oncoprex is designed to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, to target and kill cancer cells via receptor pathways, and to stimulate natural immune responses against cancer. Oncoprex consists of the TUSC2 tumor suppressor gene encapsulated in a positively charged lipid nanoparticle. It is injected intravenously, specifically targeting cancer cells, which generally have a negative electrical charge.…

Continue Reading

WednesdayMay 08, 2019 10:11 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Retains Pharmaceutical Branding Agency to Oversee Lead Drug Candidate Naming Process

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) this morning announced that it has retained the services of leading pharmaceutical branding agency, Addison Whitney, representing the next step toward commercialization of its lead drug candidate. Utilizing its 28-year history, Addison Whitney will oversee the proprietary and non-proprietary drug naming process for the company’s drug candidate for non-small cell lung cancer, presently known as Oncoprex(TM) immunogene therapy. “Retaining Addison Whitney is an important step in bringing our drug candidate to market,” Genprex Chairman and CEO Rodney Varner stated in the news release. “Obtaining regulatory approval of proprietary and non-proprietary drug names is a…

Continue Reading

ThursdayMay 02, 2019 3:14 pm

BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data in Lung Cancer Treatment Study

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) recently reported that positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody was recorded by its University of Texas MD Anderson Cancer Center collaborators in a lung cancer treatment study (http://nnw.fm/8E4bC). An article discussing the study reads, “The results of the study, which analyzed the combination of the TUSC2 gene and anti-PD1 antibody pembrolizumab, were presented in a poster at the 2019 American Association of Cancer Research Meeting. TUCS2 is a tumor suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy. . . . The poster data showed…

Continue Reading